• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Murphy Edward L. was granted 1,695 shares, increasing direct ownership by 18% to 11,084 units (SEC Form 4)

    5/27/26 4:03:24 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Murphy Edward L.

    (Last)(First)(Middle)
    2401 S. FOOTHILL DRIVE SUITE D

    (Street)
    SALT LAKE CITY UTAH 84109

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Co-Diagnostics, Inc. [ CODX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/23/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/23/2026A1,695(1)A$0.0011,084D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Unit$0.0005/23/2026M1,695 (1) (1)Common Stock5,695$0.004,000D
    Explanation of Responses:
    1. Included in 2,334 restricted stock units awarded to the Reporting Person on June 12, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2023. Included in 3,667 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2024. Included in 4,167 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2025.
    Remarks:
    /s/ Edward L. Murphy05/27/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $CODX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

    SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Dr. Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k)

    7/16/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand

    Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partnerWorkshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnosticsSALT LAKE CITY, July 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the United Nations Office for Project Services' (UNOPS) Global Implementation Workshop on Near Point of Care (NP

    7/8/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

    More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runsAnalytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® inst

    7/1/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Co-Diagnostics Inc.

    DEF 14A - Co-Diagnostics, Inc. (0001692415) (Filer)

    7/21/26 9:00:24 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Co-Diagnostics Inc.

    PRE 14A - Co-Diagnostics, Inc. (0001692415) (Filer)

    7/9/26 6:18:23 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.

    SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)

    6/3/26 4:22:01 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:04:45 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:04:12 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    President Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)

    4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

    5/27/26 4:03:48 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics downgraded by Sidoti with a new price target

    Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

    8/12/22 9:07:51 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Sidoti initiated coverage on Co-Diagnostics with a new price target

    Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

    12/29/21 8:45:34 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

    HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

    11/12/21 6:13:11 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Leadership Updates

    Live Leadership Updates

    View All

    Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

    SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Dr. Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k)

    7/16/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

    SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

    4/4/24 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

    SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

    8/29/23 9:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/13/24 5:02:32 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    2/9/22 3:43:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

    SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

    7/12/21 8:29:19 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    $CODX
    Financials

    Live finance-specific insights

    View All

    Co-Diagnostics Reports First Quarter 2026 Financial Results

    Advancing Global Commercialization Through CoSara Regulatory Progress and Regional ExpansionExecuting Clinical Strategy with Upper Respiratory Submission Preparation and TB Study InitiationExpanding International Presence and Reinforcing Platform Differentiation Through Partnerships and IPSALT LAKE CITY, May 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the first quarter ended March 31, 2026.

    5/14/26 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast

    SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    4/30/26 9:00:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care

    Co-Diagnostics Reports Full Year 2025 Financial Results

    Advancing Global Commercialization Strategy Through CoSara and CoMira Joint VenturesProgressing Clinical Pipeline and Regulatory Pathways for PCR PlatformStrengthening Technology Leadership with AI Integration and Expanding IP PortfolioSALT LAKE CITY, March 31, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financia

    3/31/26 4:01:00 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care